A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017
BACKGROUND: Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure—Quality of Care...
Published in: | Experimental Hematology & Oncology |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
BioMed Central
2021
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869509/ http://www.ncbi.nlm.nih.gov/pubmed/33557940 https://doi.org/10.1186/s40164-021-00198-2 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:7869509 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:7869509 2023-05-15T16:52:28+02:00 A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 Keykhaei, Mohammad Masinaei, Masood Mohammadi, Esmaeil Azadnajafabad, Sina Rezaei, Negar Saeedi Moghaddam, Sahar Rezaei, Nazila Nasserinejad, Maryam Abbasi-Kangevari, Mohsen Malekpour, Mohammad-Reza Ghamari, Seyyed-Hadi Haghshenas, Rosa Koliji, Kamyar Kompani, Farzad Farzadfar, Farshad 2021-02-08 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869509/ http://www.ncbi.nlm.nih.gov/pubmed/33557940 https://doi.org/10.1186/s40164-021-00198-2 en eng BioMed Central http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869509/ http://www.ncbi.nlm.nih.gov/pubmed/33557940 http://dx.doi.org/10.1186/s40164-021-00198-2 © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. CC0 PDM CC-BY Exp Hematol Oncol Research Text 2021 ftpubmed https://doi.org/10.1186/s40164-021-00198-2 2021-02-14T01:37:29Z BACKGROUND: Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure—Quality of Care Index (QCI)—to appraise the quality of care in different populations. METHODS: The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0–100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs. RESULTS: Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing. CONCLUSIONS: The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access. Text Iceland PubMed Central (PMC) New Zealand Experimental Hematology & Oncology 10 1 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Research |
spellingShingle |
Research Keykhaei, Mohammad Masinaei, Masood Mohammadi, Esmaeil Azadnajafabad, Sina Rezaei, Negar Saeedi Moghaddam, Sahar Rezaei, Nazila Nasserinejad, Maryam Abbasi-Kangevari, Mohsen Malekpour, Mohammad-Reza Ghamari, Seyyed-Hadi Haghshenas, Rosa Koliji, Kamyar Kompani, Farzad Farzadfar, Farshad A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 |
topic_facet |
Research |
description |
BACKGROUND: Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure—Quality of Care Index (QCI)—to appraise the quality of care in different populations. METHODS: The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0–100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs. RESULTS: Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing. CONCLUSIONS: The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access. |
format |
Text |
author |
Keykhaei, Mohammad Masinaei, Masood Mohammadi, Esmaeil Azadnajafabad, Sina Rezaei, Negar Saeedi Moghaddam, Sahar Rezaei, Nazila Nasserinejad, Maryam Abbasi-Kangevari, Mohsen Malekpour, Mohammad-Reza Ghamari, Seyyed-Hadi Haghshenas, Rosa Koliji, Kamyar Kompani, Farzad Farzadfar, Farshad |
author_facet |
Keykhaei, Mohammad Masinaei, Masood Mohammadi, Esmaeil Azadnajafabad, Sina Rezaei, Negar Saeedi Moghaddam, Sahar Rezaei, Nazila Nasserinejad, Maryam Abbasi-Kangevari, Mohsen Malekpour, Mohammad-Reza Ghamari, Seyyed-Hadi Haghshenas, Rosa Koliji, Kamyar Kompani, Farzad Farzadfar, Farshad |
author_sort |
Keykhaei, Mohammad |
title |
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 |
title_short |
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 |
title_full |
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 |
title_fullStr |
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 |
title_full_unstemmed |
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 |
title_sort |
global, regional, and national survey on burden and quality of care index (qci) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 |
publisher |
BioMed Central |
publishDate |
2021 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869509/ http://www.ncbi.nlm.nih.gov/pubmed/33557940 https://doi.org/10.1186/s40164-021-00198-2 |
geographic |
New Zealand |
geographic_facet |
New Zealand |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Exp Hematol Oncol |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869509/ http://www.ncbi.nlm.nih.gov/pubmed/33557940 http://dx.doi.org/10.1186/s40164-021-00198-2 |
op_rights |
© The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
op_rightsnorm |
CC0 PDM CC-BY |
op_doi |
https://doi.org/10.1186/s40164-021-00198-2 |
container_title |
Experimental Hematology & Oncology |
container_volume |
10 |
container_issue |
1 |
_version_ |
1766042755842179072 |